AR074685A1 - DERIVATIVES OF 6-CICLOAMINO -2,3-DI- PIRIDINIL-IMIDAZO (1,2-BETA) -PIRIDAZINA, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES PHOSPHORILATION OF CASEINAS QUINASA 1 EPSILON AND DELTA. - Google Patents

DERIVATIVES OF 6-CICLOAMINO -2,3-DI- PIRIDINIL-IMIDAZO (1,2-BETA) -PIRIDAZINA, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES PHOSPHORILATION OF CASEINAS QUINASA 1 EPSILON AND DELTA.

Info

Publication number
AR074685A1
AR074685A1 ARP090104907A ARP090104907A AR074685A1 AR 074685 A1 AR074685 A1 AR 074685A1 AR P090104907 A ARP090104907 A AR P090104907A AR P090104907 A ARP090104907 A AR P090104907A AR 074685 A1 AR074685 A1 AR 074685A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
atom
groups
cycloalkyl
Prior art date
Application number
ARP090104907A
Other languages
Spanish (es)
Inventor
Mireille Sevrin
Pascal George
Frederic Puech
Yulin Chang
William A Metz
Mathieu Barrague
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR074685A1 publication Critical patent/AR074685A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Derivados de 6-cicloamino-3-(1H-pirrolo[2,3-b]piridin-4-il)imidazo[1,2-b]piridazina. Procedimiento de preparación y aplicación en terapéutica de enfermedades mediadas por la caseína quinasa. Reivindicación 1: Compuesto de fórmula general (1) en la que R2 representa un grupo piridinilo eventualmente sustituido con uno o varios sustituyentes elegidos entre los átomos de halógeno y los grupos alquilo C1-6; R3 representa un átomo de H o un grupo alquilo C1-3; A representa un grupo alquileno C1-7 eventualmente sustituido con uno o dos grupos Ra; B representa un grupo alquileno C1-7 eventualmente sustituido con un grupo Rb; L representa, o un átomo de N eventualmente sustituido con un grupo Rc o Rd, o un átomo de C sustituido con un grupo Re1 y un grupo Rd o dos grupos Re2; estando los átomos de C de A y B eventualmente sustituidos con uno o varios grupos Rf idénticos o diferentes el uno del otro; Ra, Rb y Rc se definen de forma que: dos grupos Ra pueden formar juntos un grupo alquileno C1-6; Ra y Rb pueden formar juntos un enlace o un grupo alquileno C1-6; Ra y Rc pueden formar juntos un enlace o un grupo alquileno C1-6; Rb y Rc pueden formar juntos un enlace o un grupo alquileno C1-6; Rd representa un grupo elegido entre el átomo de H y los grupos alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6, alquiltio C1-6-alquilo C1-6, alcoxi C1-6-alquilo C1-6, fluoroalquilo C1-6, bencilo, acilo C1-6, hidroxialquilo C1-6; Re1 representa un grupo -NR4R5 o una monoamina cíclica que contiene eventualmente un átomo de O, estando la monoamina cíclica eventualmente sustituida con uno o varios sustituyentes elegidos entre el átomo de F y los grupos alquilo C1-6, alcoxi C1-6, hidroxilo; dos Re2 forman con el átomo de C al que están unidos una monoamina cíclica que contiene eventualmente un átomo de O, estando esta monoamina cíclica eventualmente sustituida con uno o varios grupos Rf idénticos o diferentes el uno del otro; Rf representa un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6, alcoxi C1-6-alquilo C1-6, hidroxi-alquilo C1-6, fluoroalquilo C1-6 o bencilo; R4 y R5 representan, independientemente el uno del otro, un átomo de H o un grupo alquilo C1-6, cicloalquilo C3-7 o cicloalquil C3-7-alquilo C1-6; R7 y R8 representan, independientemente el uno del otro, un átomo de H o un grupo alquilo C1-6. En estado de base o de sal de adición a un ácido.Derivatives of 6-cycloamino-3- (1H-pyrrolo [2,3-b] pyridin-4-yl) imidazo [1,2-b] pyridazine. Procedure for the preparation and application in therapeutics of casein kinase mediated diseases. Claim 1: Compound of general formula (1) wherein R2 represents a pyridinyl group optionally substituted with one or more substituents chosen from halogen atoms and C1-6 alkyl groups; R3 represents an H atom or a C1-3 alkyl group; A represents a C1-7 alkylene group optionally substituted with one or two Ra groups; B represents a C1-7 alkylene group optionally substituted with an Rb group; L represents, or an atom of N possibly substituted with a group Rc or Rd, or a atom of C substituted with a group Re1 and a group Rd or two groups Re2; the C atoms of A and B being eventually substituted with one or several Rf groups identical or different from each other; Ra, Rb and Rc are defined such that: two Ra groups can together form a C1-6 alkylene group; Ra and Rb can together form a bond or a C1-6 alkylene group; Ra and Rc can together form a bond or a C1-6 alkylene group; Rb and Rc can together form a bond or a C1-6 alkylene group; Rd represents a group selected from the atom of H and the groups C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl, C1-6 alkyl, C1-6 alkylthio-C1-6 alkyl, C1-6 alkoxy-C1 alkyl -6, C1-6 fluoroalkyl, benzyl, C1-6 acyl, C1-6 hydroxyalkyl; Re1 represents a group -NR4R5 or a cyclic monoamine which optionally contains an O atom, the cyclic monoamine being optionally substituted with one or several substituents chosen between the F atom and the C1-6 alkyl, C1-6 alkoxy, hydroxyl groups; two Re2s form with the C atom to which a cyclic monoamine is attached which optionally contains an O atom, this cyclic monoamine being optionally substituted with one or several Rf groups identical or different from each other; Rf represents a C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl, C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 fluoroalkyl or benzyl group; R4 and R5 represent, independently of each other, an H atom or a C1-6 alkyl, C3-7 cycloalkyl or C3-7 cycloalkyl-C1-6 alkyl group; R7 and R8 represent, independently of each other, an H atom or a C1-6 alkyl group. In the base or salt state of addition to an acid.

ARP090104907A 2008-12-19 2009-12-16 DERIVATIVES OF 6-CICLOAMINO -2,3-DI- PIRIDINIL-IMIDAZO (1,2-BETA) -PIRIDAZINA, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES PHOSPHORILATION OF CASEINAS QUINASA 1 EPSILON AND DELTA. AR074685A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0807257A FR2940284B1 (en) 2008-12-19 2008-12-19 6-CYCLOAMINO-2,3-DI-PYRIDINYL-IMIDAZO-1,2-B-PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US13965208P 2008-12-22 2008-12-22

Publications (1)

Publication Number Publication Date
AR074685A1 true AR074685A1 (en) 2011-02-02

Family

ID=40848284

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104907A AR074685A1 (en) 2008-12-19 2009-12-16 DERIVATIVES OF 6-CICLOAMINO -2,3-DI- PIRIDINIL-IMIDAZO (1,2-BETA) -PIRIDAZINA, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES PHOSPHORILATION OF CASEINAS QUINASA 1 EPSILON AND DELTA.

Country Status (12)

Country Link
EP (1) EP2385946A1 (en)
JP (1) JP2012512853A (en)
KR (1) KR20110095964A (en)
CN (1) CN102325773A (en)
AR (1) AR074685A1 (en)
AU (1) AU2009329427A1 (en)
BR (1) BRPI0923182A2 (en)
CA (1) CA2747365A1 (en)
FR (1) FR2940284B1 (en)
SG (1) SG172181A1 (en)
TW (1) TW201028420A (en)
WO (1) WO2010070238A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6283688B2 (en) * 2012-12-21 2018-02-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Novel pyrazole-substituted imidazopyrazine as casein kinase 1D / E inhibitor
EP2935271B1 (en) 2012-12-21 2017-10-25 Bristol-Myers Squibb Company Novel substituted imidazoles as casein kinase 1 / inhibitors
AU2015204566A1 (en) 2014-01-09 2016-08-25 Intra-Cellular Therapies, Inc. Organic compounds
CN106661056B (en) * 2014-06-19 2019-07-05 百时美施贵宝公司 As Casein kinase 1 δ/epsilon inhibitor Imidazopyridazine derivative
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
WO2023147015A1 (en) * 2022-01-27 2023-08-03 The Broad Institute, Inc. Substituted heterocyclic csnk1 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001333A1 (en) * 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
AU2003270846B2 (en) * 2002-09-19 2006-11-23 Merck Sharp & Dohme Corp. Pyrazolopyridines as cyclin dependent kinase inhibitors
MXPA05006478A (en) * 2002-12-18 2005-09-08 Vertex Pharma Triazolopyridazines as protein kinases inhibitors.
AU2004303826A1 (en) 2003-12-11 2005-07-07 Aventis Pharmaceuticals Inc. Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase I Epsilon
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
JPWO2006070943A1 (en) * 2004-12-28 2008-06-12 武田薬品工業株式会社 Condensed imidazole compounds and uses thereof
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
DE102005042742A1 (en) * 2005-09-02 2007-03-08 Schering Ag Substituted imidazo [1,2b] pyridazines as kinase inhibitors, their production and use as pharmaceuticals
FR2918061B1 (en) * 2007-06-28 2010-10-22 Sanofi Aventis 6-CYCLOAMINO-3- (PYRIDIN-4-YL) IMIDAZO-1,2-B1-PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
FR2918986B1 (en) * 2007-07-19 2009-09-04 Sanofi Aventis Sa 6-CYCLOAMINO-3- (PYRIDAZIN-4-YL) IMIDAZO [1,2-B] -PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE

Also Published As

Publication number Publication date
CN102325773A (en) 2012-01-18
CA2747365A1 (en) 2010-06-24
SG172181A1 (en) 2011-07-28
AU2009329427A1 (en) 2011-07-07
KR20110095964A (en) 2011-08-25
FR2940284B1 (en) 2011-02-18
BRPI0923182A2 (en) 2019-09-24
WO2010070238A1 (en) 2010-06-24
EP2385946A1 (en) 2011-11-16
FR2940284A1 (en) 2010-06-25
JP2012512853A (en) 2012-06-07
TW201028420A (en) 2010-08-01

Similar Documents

Publication Publication Date Title
AR074685A1 (en) DERIVATIVES OF 6-CICLOAMINO -2,3-DI- PIRIDINIL-IMIDAZO (1,2-BETA) -PIRIDAZINA, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES PHOSPHORILATION OF CASEINAS QUINASA 1 EPSILON AND DELTA.
AR114164A1 (en) PYRIDOPYRIMIDINONES SUBSTITUTED WITH BENZYLAMINE AND DERIVATIVES AS INHIBITORS OF SOS1
AR110139A1 (en) MONO AND SPIROCYCLES COMPOUNDS CONTAINING CYCLLOBUTAN AND AZETIDINE AS INHIBITORS OF INTEGRINE AV
AR086546A1 (en) DERIVATIVES OF 7H-PURIN-8 (9H) -ONA AS JAK INHIBITORS
AR089776A1 (en) 5,8-DIHIDRO-6H-PIRAZOLO [3,4-H] QUINAZOLINAS AS IGF-1R / IR INHIBITORS
AR078786A1 (en) CHROMENONE DERIVATIVES
AR092108A1 (en) PIRIDAZINE 1.4 DISSTITUTED, ANALOGS OF THE SAME AND METHODS TO TREAT DISEASES RELATED TO SMN DEFICIENCY
AR072932A1 (en) DERIVATIVES OF 2-ALQUIL-6-CICLOAMINO-3- (PIRIDIN-4-IL) IMIDAZO [1,2-B] PIRIDAZINA, ITS PREPARATION, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND ITS APPLICATION IN THERAPEUTICS OF DISEASES MEDIATED BY CASEINA QUINASA EPSILON DELTA.
PE20130376A1 (en) [1,8] NAPHTHYRIDINES SUBSTITUTED BY 2,4-DIARYLL AS KINASE INHIBITORS FOR USE AGAINST CANCER
PE20160540A1 (en) BROMODOMINES INHIBITORS
AR087760A1 (en) HETEROCICLILAMINAS AS PI3K INHIBITORS
AR082152A1 (en) DERIVATIVES OF N- (METILSULFONIL) BENZAMIDE, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF NAV1.7
AR102213A1 (en) INHIBITORS OF HEPARAN SULPHATE BIOSYNTHESIS FOR THE TREATMENT OF DISEASES
AR069269A1 (en) DERIVATIVES OF 6- CICLOAMINO -3- (PIRIDIN-IL) IMIDAZO (1,2-BETA) - PIRIDAZINA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
AR067413A1 (en) HETEROCICLICAL COMPOUNDS CONTAINING CYCLOPENTA [D] PYRIMIDINE INHIBITORS OF AKT PROTEINQUINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHOD OF PREPARATION AND USE OF THE SAME FOR THE TREATMENT OF HYPER-TROLIFERATIVE TIPERIFERATIVE AS-ISSUES
AR093036A1 (en) PIRROLOTRIAZINONA DERIVATIVES AS PI3K INHIBITORS
AR098776A1 (en) ISOCROMENE DERIVATIVES AS INHIBITORS OF PHOSFOINOSITIDO-3 KINASES
AR089568A1 (en) HETEROCICLICAL COMPOUNDS AND THEIR METHODS OF USE
AR093795A1 (en) PIRIDINUM OXIDES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES
AR092288A1 (en) EP1 RECEIVER LIGANDS
AR055344A1 (en) DERIVATIVES OF 1-OXOINDANE AND 1-OXO-2,3-DIHYDROISOINDOL AS INHIBITORS OF P38, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE KINASE P38
AR094100A1 (en) CARBAMATE DERIVATIVES OF CYCLHEXYL AND QUINUCLIDINYL THAT HAVE ACTIVITY AS b2 ADRENERGIC AGONISTS AND AS M3 MUSCARINIC ANTAGONISTS
AR093797A1 (en) Phenylethylpyridine derivatives PDE-4 INHIBITORS
AR098621A1 (en) HETEROARILO DERIVATIVES
EA201591904A1 (en) NEW DERIVATIVES N- (2,3-DIHYDRO-1H-PIRROLO [2,3-b] PYRIDIN-5-IL) -4-HINAZOLINAMINA AND N- (2,3-DIHYDRO-1H-INDOL-5-IL) - 4-HINAZOLINAMINA AS PERK INHIBITORS

Legal Events

Date Code Title Description
FB Suspension of granting procedure